A 15-year-old female, indoor, spayed, domestic shorthair cat was presented for post-mortem evaluation with a history of sudden death. A red-brown 3 cm x 4 cm neoplastic mass was identified within the body of the pancreas, along with multiple similar nodular structures within the omentum and liver. Associated lesions included hemoperitoneum, yellow discoloration of the peritoneal wall, and severe anemia. Spindle-shaped neoplastic cells exhibiting malignancy features, which occasionally contained within the cytoplasm haematoidin crystals and/or red blood cells, were observed during cytological examination. Histologically, the neoplastic cells were organized in short streams forming vascular spaces filled with erythrocytes. Immunohistochemically, the neoplastic cells were immunolabeled for vimentin and CD31, supporting the diagnosis of hemangiosarcoma. This report offers a complete post-mortem and histological evaluation of a rare tumor in cats with an unusual location and a comparative assessment of 3 anti-CD31 antibodies.

Digestive pathologies are commonly encountered in both human and veterinary medicine, frequently requiring antibiotic intervention. However, their extensive use has contributed to the global increase in antimicrobial resistance, posing a major public health challenge. With the emergence of multidrug-resistant bacteria, alternative antimicrobial strategies are urgently needed. This study assessed the total polyphenolic content and in vitro antimicrobial activity of ethanolic extracts from Origanum majorana, Salvia officinalis, and Ribes nigrum fruits against six digestive bacterial pathogens: Escherichia coli, Salmonella enteritidis, Enterobacter cloacae, Yersinia enterocolitica, Listeria monocytogenes, and Enterococcus faecalis. Antimicrobial activity was evaluated using agar well diffusion and minimum inhibitory concentration (MIC) assays. The total polyphenolic content of the extracts was 8509.457 μg/g for Salvia officinalis, 8140.996 μg/g for Origanum majorana, and 5776.616 μg/g for Ribes nigrum. R. nigrum showed the strongest antimicrobial effect (MIC 0.002 μg/μL; MBC 0.001 μg/μL) against Y. enterocolitica. S. officinalis had the highest efficacy against E. faecalis, while O. majorana was effective against both Y. enterocolitica and E. faecalis. All extracts showed bactericidal activity with MIC index values between 0.5 and 4. These findings suggest that these polyphenol-rich plant extracts may serve as promising natural antimicrobials or as adjuvants to conventional antibiotics.

Digestive disorders such as inflammatory bowel disease (IBD) and colorectal cancer are among the most significant global health challenges, largely driven by chronic inflammation and oxidative stress. Over centuries, traditional medical systems have relied on medicinal plants to alleviate gastrointestinal conditions, and current pharmacological research is beginning to validate these ancestral practices. Many plants contain a rich diversity of bioactive compounds, including polyphenols, flavonoids, terpenes, and alkaloids, that exert antioxidant, anti‐inflammatory, and anticancer effects, making them promising candidates for complementary therapy. This review compiles and critically analyzes data from the past decade on plant extracts and isolated natural compounds tested in vitro, in vivo, and ex vivo for their protective effects on intestinal health. Evidence consistently indicates that plant‐derived molecules can suppress inflammatory mediators, modulate oxidative stress responses, restore epithelial barrier integrity, and induce apoptosis in neoplastic cells. Among these, polyphenols and flavonoids emerge as key contributors, demonstrating efficacy across multiple biological models. The findings support the growing integration of traditional herbal knowledge with modern biomedical science. Plant‐based compounds represent not only valuable sources of therapeutic agents but also a foundation for developing functional foods and nutraceuticals aimed at reducing inflammation and preventing colon‐related pathologies.

Colorectal cancer remains a significant global health challenge, highlighting the need for targeted therapeutic strategies. Plant-derived bioactive compounds are of interest due to their antiproliferative and pro-apoptotic properties. This study investigated the total phenolic and flavonoid contents, antioxidant activity and anticancer potential of Origanum majorana, Salvia officinalis, and Ribes nigrum extracts using normal human intestinal epithelial cells (HIEC-6) and human colorectal carcinoma cells (HCT-116). Cell viability was assessed using the MTT assay, while apoptosis and necrosis were evaluated by Annexin V-FITC/propidium iodide staining followed by flow cytometry. Ribes nigrum exhibited the highest phenolic content and antioxidant activity, whereas Origanum majorana contained the highest flavonoid concentration. All tested extracts reduced HCT-116 cell viability in a concentration-dependent manner while maintaining high viability in HIEC-6 cells (>93%). At the highest tested concentration, R. nigrum and S. officinalis reduced HCT-116 viability to approximately 13–14% and 16–18%, respectively, whereas O. majorana reduced viability to 18–19%. Annexin V/PI analysis demonstrated marked increases in late apoptotic and necrotic populations in HCT-116 cells, confirming selective pro-apoptotic activity. Overall, these extracts demonstrated selective antiproliferative and pro-apoptotic activities while exerting minimal toxicity toward normal intestinal epithelial cells. These findings support the potential of extracts as complementary sources of bioactive compounds for colorectal cancer prevention and therapy.